Clinical trial · Interventional
Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients
Prevention of Venous Thrombosis in Cancer Patients: A Prospective, Randomized, Double-blind Study Comparing Two Different Dosages of Low-molecular Weight Heparin
NCT00375076CI-TRIAL-00002647completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In a prospective, randomized, double-blind trial, the effects of two different dosages of LMWH (5000 anti-Xa U od sc and 10 000 anti-Xa U od sc daily) on markers of hemostatic system and thrombin generation will be investigated in non-surgical cancer patients will be investigated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| enoxaparin | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients (\> 18 years) with active cancer and at least one of the following indications for thromboprophylaxis with LMWH: * Immobilization * History of VTE * Acute inflammation * Heart failure (NYHA class III or IV) * Respiratory failure Exclusion Criteria: * Indication for LMWH or UFH at therapeutic dosages * Treatment with antithrombotics (vitamin K antagonists, acetylsalicylic acid, clopidogrel) for reasons other than prevention of VTE (e.g. atrial fibrillation, myocardial infarction) * Contraindication for the treatment with LMWH * Major surgery within the last 4 weeks; minor surgery within the last week * Thrombocytopenia (\< 100.000/μl) * Prolonged prothrombin time * Prolonged activated partial thromboplastin time (aPTT) * History of heparin-induced thrombocytopenia * Bodyweight \< 50 kg or \> 100 kg * Renal insufficiency (creatinine \> 2 mg/dl)
References
Publications (0)
Data not yet available
No reference posted for this study.